November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more than 276,000 patients have undergone a TAVR procedure in the United States....
Heart Valve Technology
This channel includes news and new device innovations about heart valve technologies, including the aortic valve, mitral valve, pulmonic valve, and tricuspid valve. This includes information on transcatheter valve technologies like transcatheter aortic valve replacement (TAVR, or implantation TAVI), transcatheter mitral valve repair or replacement (TMVR), transcatheter and surgical valve repairs, and surgical replacement valves. Newer devices are now being used for transcatheter tricuspid valve repair replacement (TTVR).
-
-
November 17, 2020 — Boston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system.
-
Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials presented at the 2020...
-
October 29, 2020 — The late-breaking studies are one of the hallmarks of the annual Transcatheter Cardiovascular Therapeutics (TCT...
News | November 18, 2020
November 18, 2020 — The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial...
The Edwards Lifesciences Sapien 3 TAVR valve. The annual volume of TAVR has increased each year and in 2019 TAVR volume (72,991) exceeded all forms of SAVR (57,626), coinciding with the U.S. Food and Drug Administration (FDA) approval of TAVR for low-risk patients.
Feature | Heart Valve Technology | November 17, 2020
November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more...
Feature | Heart Valve Technology | November 17, 2020 | Dave Fornell, Editor
November 17, 2020 — Boston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge...
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip was the subject of two studies, including use to aid heart transplant patients. Bottom right, the Boston Scientific Acurate neo TAVR valve performed below the Sapien 3 and CoreValve Evolut.
Feature | TCT | October 29, 2020 | Dave Fornell, Editor
Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials...
Videos | Heart Valve Technology | October 19, 2020
David Cohen, M.D., presents late-breaking data from the STS/ACC Transcatheter Valve Registry (TVT) showing the impact...
Videos | Heart Valve Technology | October 19, 2020
Doctor Hans-Josef Feistritzerm, Heart Center of Leipzig, Germany, presents data on the use of general vs. local...
Videos | Heart Failure | October 16, 2020
The late-breaking MitraBridge Study was presented at Transcatheter Cardiovascular Therapeutics (TCT) 2020 meeting...
The Keystone Heart TriGuard 3 (TG3) is a self-stabilizing cerebral embolic deflection filter used in patients undergoing transcatheter aortic valve replacement (TAVR). The device is designed to reduce TAVR complications of cerebral embolization and ischemic stroke.
News | Heart Valve Technology | October 15, 2020
October 15, 2020 – The REFLECT II randomized clinical trial evaluating the safety and efficacy of the Keystone Heart...
The Boston Scientific Acurate neo self-expanding TAVR valve (left) did not perform as well clinically as the Medtronic CoreValve Evolut TAVR valve (right) in the SCOPE II trial presented at TCT 2020.
Feature | Heart Valve Technology | October 15, 2020
October 15, 2020 – The SCOPE II trial comparing the Boston Scientific Acurate neo vs. Medtronic CoreValve Evolut TAVR...
An illustration showing the MitraClip catheter entering the left atrium through a transseptal puncture.
News | Heart Valve Technology | October 15, 2020
October 15, 2020 – The MITHRAS randomized clinical trial found that interventional closure of an iatrogenic atrial...
Medtronic is starting a randomized, head-to-head study comparing the Medtronic CoreValve Evolut Pro and Pro+TAVR Systems against the balloon-expandable Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valvestwo transcatheter aortic valve replacement (TAVR) systems in patients with severe symptomatic aortic stenosis (ssAS).
News | Heart Valve Technology | October 14, 2020
October 14, 2020 — Medtronic announced it is starting a randomized, head-to-head study comparing two transcatheter...
Flexible electronics have been developed to implant in patients to constantly monitor their cardiac condition.
Feature | October 09, 2020 | Udi Nussinovitch M.D., Ph.D.
This is an overview of some of the biggest cardiology technology advances. These innovations are covered in more detail...
News | Heart Valve Technology | October 02, 2020
October 2, 2020 — Cardiac Dimensions announced the company has closed a $17.5 million Series C financing that will be...
News | Heart Valve Technology | September 29, 2020
September 29, 2020 — Boston Scientific launched the Acurate neo2 transcatheter aortic valve replacement (TAVR) system...
The VitalPatch RTM biosensor is being used in the TELESTAR-TAVR clinical study to evaluate patients who undergo a transcatheter aortic valve replacement (TAVR) and monitor them following the procedure utilizing the latest technology from VitalConnect, VistaSolution LIVE.
News | Wearables | September 25, 2020
September 25, 2020 — Remote and in-hospital wearable biosensor technology company VitalConnect Inc. has started the...
